Alumis Inc. Overview
ALMS market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
ALMS price chart · 1M
- O
- 5.88
- H
- 6.03
- L
- 5.84
- C
- 5.99
- Vol
- 18,123.00
Daily history from Jun 28, 2024
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $5.88
- Previous Close
- $5.85
- Day High
- $6.03
- Day Low
- $5.84
- 52 Week High
- $31.30
- 52 Week Low
- $4.41
- 7 Day Return
- -11.20%
- 30 Day Return
- -11.66%
- 90 Day Return
- -78.24%
- 1 Year Return
- +27.07%
- Daily Notional Volume
- $108.5K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.86 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.53 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -6,114.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.39 – $31.35 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $874.4M · P/B 3.38 · P/S 154.57.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
Guggenheim Downgrades Alumis to NeutralBenzinga ·